AUS 131

Drug Profile

AUS 131

Alternative Names: AUS-131; S-equol

Latest Information Update: 22 Aug 2016

Price : $50

At a glance

  • Originator Ausio Pharmaceuticals
  • Developer Ausio Pharmaceuticals; University of Kansas Medical Center; University of Texas Health Science Center at San Antonio
  • Class Isoflavones; Small molecules
  • Mechanism of Action Estrogen receptor beta agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Benign prostatic hyperplasia; Vasomotor symptoms
  • Phase I Alzheimer's disease; Osteoporosis
  • Phase 0 Breast cancer

Most Recent Events

  • 01 Apr 2016 Ausio Pharmaceuticals completes phase-I clinical trials in Alzheimer's disease in USA (PO) (NCT02142777)
  • 31 Jan 2016 Ausio Pharmaceuticals completes a phase II trial in Benign prostatic hyperplasia in USA (NCT00962390)
  • 13 Aug 2015 Phase-II development is ogoing for Vasomotor symptoms and benign prostatic hyperplasia in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top